Bone Marrow vs. Fat-Derived Stem Cells: How Do the Sources Compare?
- Updated November 14, 2026
- Stop 4 of 6 on the Stem cell basics line
“Bone marrow-derived stem cells” and “fat-derived stem cells” are common labels, but neither guarantees that an injection contains a purified stem cell population. Bone marrow and fat contain different mixtures of cells and are collected and processed in different ways. What a product contains, and what evidence exists for it, depends on the exact preparation: same-day concentrate, stromal vascular fraction or laboratory-grown cells. The tissue named in an advertisement is only the starting point.
What is collected from bone marrow versus adipose tissue?
Bone marrow is usually collected by aspiration: a needle is placed into the pelvic bone, commonly the iliac crest at the back of the hip, and liquid marrow is drawn out. Marrow is mostly blood-forming tissue. It contains blood stem cells, developing blood cells, platelets, fat cells and a small fraction of mesenchymal stromal cells.
Adipose (fat) tissue is usually collected by liposuction, often from the abdomen or thighs. The tissue is mostly fat cells, held in a framework of connective tissue and blood vessels. Within that framework are stromal cells, cells from blood vessel walls, immune cells and others.
The two starting materials are physically different. One is a liquid tissue full of blood-forming cells; the other is a solid tissue that must be broken down before cells can be separated.
Which cells and other components may be present?
What ends up in a syringe depends on processing. Four broad product types can be blurred together under the “stem cell” label:
- Bone marrow aspirate concentrate (BMAC): marrow spun in a centrifuge the same day to concentrate cells. It is a mixture dominated by blood-forming and blood cells, with a small, variable fraction of mesenchymal stromal cells. The composition is explained in what BMAC is and what it contains.
- Stromal vascular fraction (SVF): cells separated from fat tissue, usually by enzymatic or mechanical processing. It is a mixed population of stromal, vascular and immune cells, not a purified stem cell product.
- Processed or minimally manipulated fat: fat tissue that has been washed, filtered or broken into smaller pieces, without isolating cells.
- Culture-expanded mesenchymal stromal cells: cells from marrow, fat or another source multiplied in a laboratory before use, which narrows the mix toward the stromal cells that grow in culture.
The processing path matters as much as the starting tissue: a same-day concentrate and a laboratory-grown product made from the same marrow are different products.
| Starting tissue | Processing path | Resulting product |
|---|---|---|
| Bone marrow aspirate | Same-day concentration in a centrifuge | BMAC, a mixed-cell concentrate |
| Bone marrow aspirate | Laboratory culture over days to weeks | Culture-expanded mesenchymal stromal cells |
| Fat (lipoaspirate) | Processing to separate cells from the tissue | SVF, a mixed-cell population |
| Fat (lipoaspirate) | Washing, filtering or fragmenting without isolating cells | Processed fat tissue |
| Fat (lipoaspirate) | Laboratory culture over days to weeks | Culture-expanded mesenchymal stromal cells |
This map shows pathways in general terms, not instructions for preparing any product.
How do collection and processing differ?
Marrow collection involves a needle in the hip bone, usually under local anesthesia, with the risks of a bone aspiration such as pain, bleeding and infection. Fat collection involves a minor liposuction procedure with its own risks at the harvest site.
Processing adds variability. Yields from marrow concentrate differ widely between harvest sites, techniques and studies, a point reviewed in detail in the BMAC article linked above. For fat-derived preparations, the separation method changes which cells end up in the final product and in what proportions.
Laboratory-level differences between marrow-derived and fat-derived stromal cells have been described. A 2015 study comparing the two populations characterized differences between bone marrow and adipose stromal cells in the laboratory. That kind of work describes how the cells behave under study conditions. It is not evidence that an injection of one works better than the other in a joint.
Contamination control matters for every product that leaves the body, is processed and is put back. Sterile handling, closed processing systems and testing standards differ between settings.
Can one source be called more effective?
Not on the evidence usually offered. To say marrow-derived cells work better than fat-derived cells, or the reverse, you would need trials that compare the two head to head, in the same condition, with comparable preparations, doses and outcomes. Comparing a marrow trial in one population with a fat trial in another, each using different processing and different measures, cannot settle the question.
Cell counts from different laboratories cannot be reliably compared either, unless they use comparable methods and definitions. Assays, definitions and processing methods often differ, so a higher “stem cell count” on one clinic’s sheet should not be ranked against another’s without that. If a provider claims one source is superior, ask for the head-to-head trial that shows it, for your condition.
For knee osteoarthritis, the American College of Rheumatology’s 2026 recommendation summary strongly recommends against stem cell injections without distinguishing a favored tissue source.
What about FDA regulation and unapproved uses?
FDA regulates human cells, tissues and cellular and tissue-based products (HCT/Ps). Under 21 CFR 1271.10(a), a narrow group of these can be regulated solely under section 361 of the Public Health Service Act, without premarket approval, if they meet all of the stated criteria. Two of those criteria are central here: the product must be minimally manipulated, and it must be intended for homologous use, meaning it performs the same basic function in the recipient as in the donor. FDA’s 2020 guidance on minimal manipulation and homologous use explains how it applies them.
Two consequences follow. First, a product that is more than minimally manipulated, or used for a non-homologous purpose, falls outside that narrow category. It is then regulated as a drug or biological product: it can be studied in people under an FDA Investigational New Drug (IND) application, and it can be marketed only after FDA approval for a specific use. Second, the 361 category is not a permission slip for joint injections; it is a set of conditions a product must actually meet. FDA’s rules also contain separate exceptions, such as the same surgical procedure exception in 21 CFR 1271.15(b), each with its own conditions. Which rules apply depends on the specific product and how it is prepared and used, and doing a procedure on the same day does not by itself qualify for an exception or amount to approval. FDA’s patient information page lists stromal vascular fraction among unapproved products that require FDA licensure or approval to be marketed. The list of products that have been approved is in which stem cell therapies are FDA-approved.
Is fat-derived SVF the same as purified stem cells? No. SVF is a mixed population of stromal, vascular and immune cells separated from fat tissue.
Can researchers compare stem-like cell counts across preparations without standardizing methods? Not reliably. Different assays and processing methods produce numbers that cannot be ranked against each other.
Every stop on the Stem cell basics line
- Adult Stem Cells vs. Embryonic Stem Cells: How Are They Different?
- Are Mesenchymal Stem Cells and Mesenchymal Stromal Cells the Same Thing?
- Autologous vs. Allogeneic Stem Cells: What Does Each Term Mean?
- Bone Marrow vs. Fat-Derived Stem Cells: How Do the Sources Compare?
- What Is Bone Marrow Aspirate Concentrate (BMAC), and What Does It Contain?
- What Are Exosomes, and What Do They Do in the Body?
Leave a note on this stop